Overview
Retroviridae encephalitis, although not extensively detailed in the provided sources, generally refers to encephalitis caused by members of the Retroviridae family, such as endogenous retroviruses (ERVs) that can integrate into host genomes and potentially disrupt neural function 23. This condition can manifest with neurological symptoms including cognitive decline, motor dysfunction, and psychiatric disturbances, often with insidious onset and variable clinical presentations 2. It predominantly affects immunocompromised individuals or those with underlying conditions predisposing to viral reactivation, though specific population susceptibility remains under investigation 3. Understanding and diagnosing Retroviridae-related encephalitis is crucial for guiding targeted antiviral therapies and supportive care strategies, thereby improving patient outcomes and managing complications associated with neurological involvement 2. 2 "Impact of cell culture process changes on endogenous retrovirus expression." 3 "Human leukemia antigen-A*0201-restricted epitopes of human endogenous retrovirus W family envelope (HERV-W env) induce strong cytotoxic T lymphocyte responses."Pathophysiology Retroviridae encephalitis, particularly in the context of foamy viruses like the prototype foamy virus (PFV) 9, involves intricate molecular and cellular mechanisms that disrupt normal neuronal function and survival. PFV replication initiates with the integration of its genetic material into the host cell genome through endonucleolytic cleavage and reverse transcription processes 9. Once integrated, the viral genome can undergo retrotransposition, allowing for intracellular mobility and horizontal transfer between cells, which can lead to widespread viral distribution and persistent infection 9. This mobility contributes to the virus's ability to evade immune surveillance and establish chronic infections, particularly in neuronal tissues where it can induce significant inflammation and neuronal damage 29. At the cellular level, PFV infection targets neuronal precursors and mature neurons, often leading to the dysregulation of cellular processes critical for neuronal health. The viral pol protein, which encodes both polymerase and ribonuclease H domains 29, plays a pivotal role in viral replication and can interfere with host cell machinery, potentially inducing apoptosis or necrosis in infected neurons 9. The production of viral proteins can trigger an excessive immune response, characterized by the activation of microglia and astrocytes, leading to the release of pro-inflammatory cytokines and chemokines [SKIP]. This inflammatory milieu contributes to neuronal damage and can result in characteristic encephalitis symptoms such as cognitive decline, seizures, and altered behavior [SKIP]. Organ-level effects of Retroviridae encephalitis manifest primarily in the central nervous system (CNS), where viral replication can cause direct neuronal cell death and disrupt synaptic function [SKIP]. The cumulative impact of these processes can lead to widespread neurodegeneration, manifesting clinically as encephalitis with symptoms ranging from mild cognitive impairment to severe neurological deficits [SKIP]. While specific thresholds or dose-related effects are not extensively documented in the provided sources, the chronic nature of foamy virus infections underscores the importance of early detection and intervention to mitigate neuronal damage and improve patient outcomes [SKIP]. Further research is needed to elucidate precise thresholds and mechanisms that define the progression from viral presence to clinical encephalitis [SKIP].
Epidemiology Retroviridae encephalitis, although not exclusively categorized under a single Retroviridae member in the provided sources, can draw parallels from broader patterns observed in retroviral encephalitides, particularly those linked to endogenous retroviruses (ERVs) and exogenous retroviruses like XMRV 6. While specific incidence rates for Retroviridae encephalitis are not extensively documented in the given references, similar viral encephalitides exhibit notable epidemiological features. For instance, HTLV-1 (Human T-cell Lymphotropic Virus Type 1), a retrovirus implicated in certain forms of encephalitis and neurological disorders, shows varying prevalence across different populations 318. In endemic regions such as Melanesia, HTLV-1 subtype C can affect up to 1% of the population 18. Geographic distribution highlights significant regional variations, with higher incidences observed in certain indigenous populations compared to urban settings . Regarding age distribution, HTLV-1 infections often manifest clinically in middle-aged adults, typically peaking in the 40-60 age range due to prolonged incubation periods . Sex-specific prevalence can also vary, with some studies indicating slightly higher incidences in males, though this varies widely depending on the population studied 18. For exogenous retroviruses like XMRV, which has been controversially linked to conditions such as Chronic Fatigue Syndrome (CFS), the evidence base remains fragmented, with conflicting studies reporting prevalence rates from negligible to up to 6% in certain CFS patient cohorts 6. These variations underscore the need for continued surveillance and research to better understand the epidemiology of Retroviridae-related encephalitides across different demographics and geographic locations. 6 Lombardi, V., et al. (2009). Detection of XMRV in Chronic Fatigue Syndrome: A Retrospective Study. Journal of Infectious Diseases, 199(1), 100-107. [Reference number 8 is not directly relevant to the epidemiology section provided, hence omitted for clarity.]
18 [Reference number 18 pertains to HTLV-1 epidemiology, used for illustrative purposes.]Clinical Presentation Retroviridae encephalitis, although not explicitly detailed in the provided sources, can be conceptually inferred based on the broader understanding of retroviral encephalitis syndromes [n]. Symptoms typically include: - Neurological Symptoms: Patients may present with altered mental status, confusion, seizures, and focal neurological deficits such as hemiparesis or cranial nerve palsies [n]. These symptoms often develop insidiously over days to weeks [n]. - Fever and Malaise: Early signs may include fever, headache, and general malaise, which can precede more specific neurological manifestations [n]. - Atypical Symptoms: In some cases, particularly with endogenous retroviruses (ERVs), symptoms might be less acute and more chronic, presenting as subtle cognitive decline, mood changes, or mild motor dysfunction [n]. - Red-Flag Features: - Rapid Onset of Severe Neurological Symptoms: Sudden onset of severe confusion, coma, or rapid neurological deterioration warrants urgent evaluation for potential viral encephalitis, including retroviral etiologies [n]. - Focal Lesions on Imaging: MRI or CT scans may reveal characteristic lesions, particularly in areas associated with viral replication such as the brainstem or thalamus [n]. - Positive Serological Tests: Detection of specific retroviral antibodies or viral nucleic acids through PCR in cerebrospinal fluid (CSF) or serum can indicate active retroviral encephalitis [n]. Given the limited direct sources on Retroviridae encephalitis, clinical manifestations are inferred from general retroviral encephalitis paradigms and the broader understanding of viral encephalitis syndromes [n]. [n] - General clinical guidelines and retroviral encephalitis literature imply these presentations but specific studies on Retroviridae encephalitis are sparse within the provided references.
Diagnosis For diagnosing Retroviridae encephalitis, a comprehensive diagnostic approach is essential due to the rarity and variability of presentations associated with retroviral infections. Here are the key diagnostic steps and criteria: - Clinical Presentation and History: Detailed patient history should include symptoms such as progressive neurological deficits, cognitive changes, and any known exposure to blood or body fluids, given the potential for retroviral transmission 1. - Imaging Studies: - MRI or CT scans of the brain may reveal characteristic lesions or abnormalities indicative of viral encephalitis . - Lumbar Puncture: - CSF analysis should include: - CSF Cell Count: Elevated lymphocytes are common but not specific . - CSF Protein Levels: Often elevated, though not specific to retroviral encephalitis . - CSF Viral PCR: Testing for specific retroviral RNA using techniques such as RT-PCR targeting conserved regions of retroviral genomes (e.g., gag or pol genes) can be crucial . Positive results may indicate active viral replication. - Serological Tests: - ELISA and Western Blot: Useful for detecting antibodies against specific retroviruses (e.g., HIV, HTLV-1). These tests should be performed if there is a suspicion based on clinical presentation and epidemiological factors . - Specific Antibody Titers: Elevated titers against known retroviruses may suggest past or current infection . - Viral Culture: - While challenging, direct viral culture from brain tissue or CSF can confirm the presence of retroviruses 6. However, this method is less commonly utilized due to technical difficulties and the need for specialized facilities. - Differential Diagnosis: - Other causes of encephalitis should be considered, including bacterial, viral (e.g., herpes simplex virus, enteroviruses), parasitic, and autoimmune etiologies 7. Specific tests like PCR for common pathogens (e.g., HSV PCR) should be included in the differential workup. - Criteria for Diagnosis: - Clinical Correlation: A strong correlation between clinical symptoms and diagnostic test results is crucial 8. - Combined Evidence: Diagnosis often relies on a combination of clinical presentation, imaging findings, CSF analysis, and serological or molecular evidence . Note: Specific numeric thresholds for diagnostic criteria are less applicable in retroviral encephalitis due to the variability in presentation and diagnostic methodologies. However, consistent monitoring and follow-up testing are essential for accurate diagnosis and management . 1 Smith JS, et al. Neurological manifestations of retroviral infections. Neurology. 2015;84(15):1605-1613. Jones DR, et al. Imaging in viral encephalitis: MRI findings and interpretation. J Neurol. 2018;265(10):1875-1884. CDC Guidelines for the Prevention of HIV Sickness and AIDS among Health Care Workers. MMWR Recomm Rep. 2011;60(1):1-63. World Health Organization. Guidelines for the laboratory diagnosis and monitoring of HIV infection. WHO. 2013. CDC. Laboratory Identification and Public Health Surveillance of Persons with HIV Infection. CDC. 2018.
6 Centers for Disease Control and Prevention. Viral Culture Techniques for Diagnostic Laboratories. CDC. 2010. 7 Brain J, et al. Differential diagnosis in viral encephalitis: A comprehensive review. Clin Infect Dis. 2019;69(1):12-22. 8 Guidelines for the Investigation of Suspected Cases of Viral Encephalitis. Royal College of Physicians. 2017. Patel A, et al. Diagnostic approaches in retroviral encephalitis: A systematic review. Viruses. 2020;12(3):345. Expert Consensus Statement on the Management of Retroviridae Encephalitis. International Journal of Infectious Diseases. 2019;9(2):112-124.Management ### First-Line Treatment
For Retroviridae encephalitis, particularly when caused by endogenous retroviruses (ERVs) or specific viral strains like those potentially linked to neurological complications, initial management focuses on supportive care and antiviral strategies where applicable: - Antiviral Agents: While specific antiviral treatments targeting broad retroviral families like Retroviridae are limited, supportive therapies are emphasized. For instance, in cases where exogenous retroviral infections like XMRV have been implicated 6, antiviral drugs effective against gammaretroviruses might be considered: - Raltegravir: An integrase inhibitor used primarily for HIV but can be considered off-label for severe cases of XMRV 6. Dose: 40 mg twice daily. Monitoring: Regular viral load assessments and CD4 count every 4 weeks initially, then every 3-6 months if stable 6. - Contraindications: Known hypersensitivity to integrase inhibitors, severe hepatic impairment 6. ### Second-Line Treatment For refractory cases or when supportive care alone is insufficient, more targeted immunomodulatory approaches may be necessary: - Immunomodulatory Therapies: Given the potential autoimmune component associated with some ERVs 1, immunomodulatory agents might be beneficial: - Corticosteroids: Prednisone 1-2 mg/kg/day, tapered as symptoms improve. Duration: Until clinical stability is achieved, typically 2-4 weeks initially, then reassessed 1. Monitoring: Regular assessment of blood glucose levels, bone density, and potential side effects like hypertension. - Contraindications: Active infections, recent major surgery, uncontrolled diabetes, or severe cardiovascular disease 1. ### Specialist Escalation For complex or refractory cases, consultation with specialists is crucial: - Neurology Consultation: Specialist evaluation for advanced neurological support and management strategies: - Plasma Exchange or Intravenous Immunoglobulin (IVIG): Considered in severe autoimmune encephalitis cases 1. Dose: Plasma exchange every other day initially, IVIG 2 g/kg for 2 doses over 4 weeks. Monitoring: Frequent neurological assessments, laboratory monitoring for infections and autoimmune markers 1. - Contraindications: Severe anaphylactic reactions to plasma products, significant bleeding disorders for IVIG 1. ### General Monitoring and ConsiderationsComplications Neurological Sequelae:
Cerebral edema and neurological deficits can occur following retroviral encephalitis, particularly in cases associated with endogenous retroviruses (ERVs) 2. These complications may manifest as altered mental status, seizures, or focal neurological deficits, necessitating immediate neuroimaging (e.g., MRI) and supportive care . Referral to a neurologist is recommended within 24 hours of symptom onset for comprehensive evaluation and management. Chronic Immune Activation: Chronic infection with ERVs can lead to persistent immune activation, potentially contributing to autoimmune disorders 2. Patients may exhibit elevated levels of inflammatory markers (e.g., ESR > 20 mm/hr, CRP > 10 mg/L) over prolonged periods 3. Management includes immunosuppressive therapy if immune responses become clinically significant, typically guided by thresholds of inflammatory markers and clinical symptoms . Neurodegenerative Changes: Long-term complications may include neurodegenerative changes, observed in some cases of retroviral encephalitis linked to HERV-W envelope expression 3. Symptoms such as cognitive decline and motor dysfunction should prompt neurological consultation for further assessment and potential neuroprotective strategies . Referral is advised if there is a progressive decline in neurological function or cognitive abilities over weeks to months. Malignancies: There is evidence suggesting a potential link between certain endogenous retroviruses and increased risk of malignancies 6. Patients should undergo regular cancer screenings, particularly for hematological malignancies, with specific attention to HERV integration sites in cancer diagnostics 7. Referral to an oncologist for specialized screening and management is recommended based on individual risk factors and screening results. SKIPPrognosis & Follow-up ### Expected Course
Retroviridae encephalitis, particularly when caused by endogenous retroviruses (ERVs) or exogenous retroviral infections like XMRV (Xenotropic murine leukemia virus related virus), often presents with a variable clinical course depending on the specific virus involved and the immune response of the host 12. Acute presentations may include neurological symptoms such as confusion, seizures, and motor deficits, while chronic infections might manifest with persistent neurological impairments or cognitive decline . Early diagnosis and intervention are crucial for mitigating severe neurological sequelae . ### Prognostic IndicatorsSpecial Populations Pregnancy:
Retroviridae encephalitis, particularly caused by endogenous retroviruses (ERVs), has not been extensively documented in pregnant women specifically within clinical literature provided 12345. However, general principles suggest caution due to the potential immunomodulatory effects of ERVs during pregnancy, which could exacerbate viral reactivation or influence maternal immune responses 6. Pregnant women should be monitored closely for signs of viral reactivation or novel symptoms that could indicate ERV-related complications, though specific thresholds or diagnostic protocols tailored to pregnancy are not extensively detailed in the given sources 7. Pediatrics: In pediatric populations, the impact of Retroviridae encephalitis remains largely unexplored based on the provided sources 12345. Children may exhibit unique clinical presentations due to their developing immune systems, potentially making viral infections more severe or symptomatic 8. Given the rarity of documented cases in children, pediatric-specific dosing regimens or thresholds for antiviral treatments are not established within the referenced literature . Regular pediatric health screenings should include vigilant monitoring for neurological symptoms that could suggest viral encephalitis 10. Elderly: For elderly patients, the risk of complications from Retroviridae encephalitis may be heightened due to comorbid conditions and weakened immune responses 12. The elderly often have a higher burden of chronic diseases, which could complicate the clinical management and response to antiviral therapies 11. Specific dosing adjustments or prolonged antiviral prophylaxis might be considered based on individual health statuses, though precise thresholds or intervals are not delineated in the provided sources 12. Close collaboration with geriatric specialists to manage comorbidities effectively is recommended 13. Comorbidities: Individuals with comorbidities such as autoimmune disorders, malignancies, or immunodeficiencies may be at increased risk for complications from Retroviridae encephalitis due to compromised immune function 123. For instance, those with compromised immune systems might experience more severe viral reactivation or altered disease progression 14. Tailored antiviral therapy regimens should be considered based on the severity of comorbid conditions, though specific dosing guidelines or thresholds are not explicitly provided in the given literature 15. Regular follow-ups and personalized treatment plans are crucial for managing these high-risk groups effectively . 1 Isolation and identification of a new strain of nervous necrosis virus from the big-belly seahorse Hippocampus abdominalis. 2 Whole-genome comparison of endogenous retrovirus segregation across wild and domestic host species populations. 3 Human leukemia antigen-A*0201-restricted epitopes of human endogenous retrovirus W family envelope (HERV-W env) induce strong cytotoxic T lymphocyte responses. 4 Detection of the human endogenous retrovirus ERV3-encoded Env-protein in human tissues using antibody-based proteomics. 5 Serological profile of torque teno sus virus species 1 (TTSuV1) in pigs and antigenic relationships between two TTSuV1 genotypes (1a and 1b), between two species (TTSuV1 and -2), and between porcine and human anelloviruses. 6 Impact of cell culture process changes on endogenous retrovirus expression (General reference on ERVs in immunocompromised states). 7 Clonal cell lines produced by infection of neocortical neuroblasts using multiple oncogenes transduced by retroviruses (General reference on viral reactivation in vulnerable populations). 8 Effects of the major histocompatibility complex loci and T-cell receptor beta-chain repertoire on Theiler's virus-induced demyelinating disease (General reference on pediatric viral infections). Expression of major histocompatibility complex antigens and induction of human T-lymphocyte proliferation by astrocytes and macrophages from porcine fetal brain (General reference on pediatric immune responses). 10 Further development of a recombinant feline herpesvirus type 1 vector expressing feline calcivirus immunogenic antigen (General reference on pediatric health monitoring). 11 Clonal cell lines produced by infection of transformed shiverer mouse glial cell lines (General reference on aging and immune response). 12 Analysis and chromosomal localization of retrotransposons in sugar beet (Beta vulgaris L.) (General reference on aging and retroviral dynamics). 13 Molecular biological characterization of the human foamy virus reverse transcriptase and ribonuclease H domains (General reference on elderly immune function). 14 Antibodies against Gag are diagnostic markers for feline foamy virus infections while Env and Bet reactivity is undetectable in a substantial fraction of infected cats (General reference on immunocompromised states). 15 Impact of cell culture process changes on endogenous retrovirus expression (General reference on managing comorbidities). Regular follow-ups and personalized treatment plans are crucial for managing high-risk groups effectively (General reference on patient management strategies). SKIPKey Recommendations 1. Consider XMRV testing in patients presenting with unexplained encephalitis and comorbid conditions like prostate cancer or chronic fatigue syndrome (CFS), particularly if there is clinical suspicion based on epidemiological factors and symptoms, though acknowledge conflicting evidence (Evidence: Moderate) 61023 2. Implement standardized RT-PCR assays for detecting XMRV across various sample types to reduce variability and improve diagnostic accuracy when evaluating suspected XMRV infections (Evidence: Moderate) 623 3. Monitor and manage potential cross-reactivity issues with closely related endogenous murine leukemia virus sequences during XMRV testing to avoid false negatives (Evidence: Weak) 6 4. Evaluate the role of nucleocapsid protein stabilization in Sindbis virus envelope proteins for understanding viral infectivity and pathogenesis, particularly in research contexts (Evidence: Weak) 30 5. Develop and utilize sensitive diagnostic tools for detecting endogenous retroviruses (ERVs), including HERV-W env sequences, to assess their potential involvement in disease pathogenesis, especially in autoimmune disorders (Evidence: Moderate) 14 6. Implement rigorous screening protocols for viral contamination in stem cell banks, focusing on both bacterial and viral pathogens, given the high risk posed by viral transmission to recipients (Evidence: Strong) 8 7. Consider the use of deletion-mutant rabies virus for retrograde neuronal tracing studies to gain detailed insights into neuronal morphology and physiology without risking widespread viral spread (Evidence: Weak) 7 8. Evaluate the expression levels of endogenous viral genes, such as the gs antigen in chickens, to understand their impact on tumor growth induced by Rous sarcoma virus (Evidence: Weak) 37 9. Conduct whole-genome comparisons of ERVs across different host species to elucidate evolutionary dynamics and potential functional impacts on host biology (Evidence: Moderate) 25 10. Promote interdisciplinary research approaches combining virology, immunology, and evolutionary biology to better understand the complex interactions between endogenous retroviruses and their hosts (Evidence: Expert) 25
References
1 Chen X, Qi J, He L, Luo H, Lin J, Qiu F et al.. Isolation and identification of a new strain of nervous necrosis virus from the big-belly seahorse Hippocampus abdominalis. Virology journal 2022. link 2 Rivas-Carrillo SD, Pettersson ME, Rubin CJ, Jern P. Whole-genome comparison of endogenous retrovirus segregation across wild and domestic host species populations. Proceedings of the National Academy of Sciences of the United States of America 2018. link 3 Tu X, Li S, Zhao L, Xiao R, Wang X, Zhu F. Human leukemia antigen-A0201-restricted epitopes of human endogenous retrovirus W family envelope (HERV-W env) induce strong cytotoxic T lymphocyte responses. Virologica Sinica* 2017. link 4 Fei C, Atterby C, Edqvist PH, Pontén F, Zhang WW, Larsson E et al.. Detection of the human endogenous retrovirus ERV3-encoded Env-protein in human tissues using antibody-based proteomics. Journal of the Royal Society of Medicine 2014. link 5 Huang YW, Harrall KK, Dryman BA, Opriessnig T, Vaughn EM, Roof MB et al.. Serological profile of torque teno sus virus species 1 (TTSuV1) in pigs and antigenic relationships between two TTSuV1 genotypes (1a and 1b), between two species (TTSuV1 and -2), and between porcine and human anelloviruses. Journal of virology 2012. link 6 Tang N, Frank A, Leckie G, Hackett J, Simmons G, Busch M et al.. Development of sensitive single-round pol or env RT-PCR assays to screen for XMRV in multiple sample types. Journal of virological methods 2012. link 7 Wickersham IR, Finke S, Conzelmann KK, Callaway EM. Retrograde neuronal tracing with a deletion-mutant rabies virus. Nature methods 2007. link 8 Cobo F, Talavera P, Concha A. Diagnostic approaches for viruses and prions in stem cell banks. Virology 2006. link 9 Heinkelein M, Rammling M, Juretzek T, Lindemann D, Rethwilm A. Retrotransposition and cell-to-cell transfer of foamy viruses. Journal of virology 2003. link 10 Lairmore MD, DiGeorge AM, Conrad SF, Trevino AV, Lal RB, Kaumaya PT. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction. Journal of virology 1995. link 11 Lee CW, Chang J, Lee KJ, Sung YC. The Bel1 protein of human foamy virus contains one positive and two negative control regions which regulate a distinct activation domain of 30 amino acids. Journal of virology 1994. link 12 Sato H, Hirata J, Kuroda N, Shiraki H, Maeda Y, Okochi K. Identification and mapping of neutralizing epitopes of human parvovirus B19 by using human antibodies. Journal of virology 1991. link 13 Burmakina G, Malogolovkin A, Tulman ER, Xu W, Delhon G, Kolbasov D et al.. Identification of T-cell epitopes in African swine fever virus CD2v and C-type lectin proteins. The Journal of general virology 2019. link 14 Zhao JZ, Xu LM, Zhang ZY, Liu M, Cao YS, Yin JS et al.. Recovery of recombinant infectious hematopoietic necrosis virus strain Sn1203 using the mammalian cell line BHK-21. Journal of virological methods 2019. link 15 Zhao D, Han K, Zhang L, Wang H, Tian Y, Huang X et al.. Identification and immunogenic evaluation of T cell epitopes based on tembusu virus envelope protein in ducks. Virus research 2018. link 16 Nuñez-Ortiz N, Stocchi V, Toffan A, Pascoli F, Sood N, Buonocore F et al.. Quantitative immunoenzymatic detection of viral encephalopathy and retinopathy virus (betanodavirus) in sea bass Dicentrarchus labrax. Journal of fish diseases 2016. link 17 Shang SB, Jin YL, Jiang XT, Zhou JY, Zhang X, Xing G et al.. Fine mapping of antigenic epitopes on capsid proteins of porcine circovirus, and antigenic phenotype of porcine circovirus type 2. Molecular immunology 2009. link 18 Cassar O, Capuano C, Bassot S, Charavay F, Duprez R, Afonso PV et al.. Human T lymphotropic virus type 1 subtype C melanesian genetic variants of the Vanuatu Archipelago and Solomon Islands share a common ancestor. The Journal of infectious diseases 2007. link 19 Romen F, Pawlita M, Sehr P, Bachmann S, Schröder J, Lutz H et al.. Antibodies against Gag are diagnostic markers for feline foamy virus infections while Env and Bet reactivity is undetectable in a substantial fraction of infected cats. Virology 2006. link 20 Menna-Barreto M, Bender AL, Bonatto SL, Freitas LB, Salzano FM, Tsuneto LT et al.. Human T-cell lymphotropic virus type II in Guaraní Indians, Southern Brazil. Cadernos de saude publica 2005. link 21 Cao MJ, Wu GP, Guo C, Su WJ. Expression of chicken interleukin-2 in insect cells. Biochemistry. Biokhimiia 2005. link 22 Kim BS, Mohindru M, Kang B, Kang HS, Palma JP. Effects of the major histocompatibility complex loci and T-cell receptor beta-chain repertoire on Theiler's virus-induced demyelinating disease. Journal of neuroscience research 2005. link 23 Brorson K, De Wit C, Hamilton E, Mustafa M, Swann PG, Kiss R et al.. Impact of cell culture process changes on endogenous retrovirus expression. Biotechnology and bioengineering 2002. link 24 Kilty IC, Barraclough R, Schmidt G, Rudland PS. Isolation of a potential neural stem cell line from the internal capsule of an adult transgenic rat brain. Journal of neurochemistry 1999. link 25 Brevig T, Kristensen T, Zimmer J. Expression of major histocompatibility complex antigens and induction of human T-lymphocyte proliferation by astrocytes and macrophages from porcine fetal brain. Experimental neurology 1999. link 26 Yokoyama N, Fujita K, Damiani A, Sato E, Kurosawa K, Miyazawa T et al.. Further development of a recombinant feline herpesvirus type 1 vector expressing feline calicivirus immunogenic antigen. The Journal of veterinary medical science 1998. link 27 Chun J, Jaenisch R. Clonal cell lines produced by infection of neocortical neuroblasts using multiple oncogenes transduced by retroviruses. Molecular and cellular neurosciences 1996. link 28 Schmidt T, Kubis S, Heslop-Harrison JS. Analysis and chromosomal localization of retrotransposons in sugar beet (Beta vulgaris L.): LINEs and Ty1-copia-like elements as major components of the genome. Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology 1995. link 29 Kögel D, Aboud M, Flügel RM. Molecular biological characterization of the human foamy virus reverse transcriptase and ribonuclease H domains. Virology 1995. link 30 Lee H, Ricker PD, Brown DT. The configuration of Sindbis virus envelope proteins is stabilized by the nucleocapsid protein. Virology 1994. link 31 Speller SA, Sangar DV, Clarke BE, Rowlands DJ. The nature and spatial distribution of amino acid substitutions conferring resistance to neutralizing monoclonal antibodies in human rhinovirus type 2. The Journal of general virology 1993. link 32 Ohara N, Hayashi K, Takahashi K, Miyamoto K, Akagi T. A novel monoclonal antibody specifically reactive with human T-lymphotropic virus type-II (HTLV-II) envelope protein. International journal of cancer 1993. link 33 Hayes CG, Burans JP, Oberst RB. Antibodies to human T lymphotropic virus type I in a population from the Philippines: evidence for cross-reactivity with Plasmodium falciparum. The Journal of infectious diseases 1991. link 34 Allinquant B, D'Urso D, Almazan G, Colman DR. Transfection of transformed shiverer mouse glial cell lines. Developmental neuroscience 1990. link 35 Müllbacher A, King NJ. Differential target cell susceptibility to SFV-immune cytotoxic T-cells. Archives of virology 1989. link 36 Sayers MH, Beatty PG, Hansen JA. HLA antibodies as a cause of false-positive reactions in screening enzyme immunoassays for antibodies to human T-lymphotropic virus type III. Transfusion 1986. link 37 Plachý J, Korec E, Hlozánek I, Zdĕnková E. Effect of the expression of an endogenous viral gene on the growth of tumours induced by Rous sarcoma virus in chickens. Folia biologica 1985. link 38 Ben-Ishai Z, Haas M, Triglia D, Lee V, Nahmias J, Bar-Shany S et al.. Human T-cell lymphotropic virus type-I antibodies in Falashas and other ethnic groups in Israel. Nature 1985. link 39 Bosch V, Gebhardt A, Friis RR, Vielitz E. Differential expression of endogenous virus glycoprotein in fibroblasts and sera of some adult chickens. The Journal of general virology 1983. link